clinical trial · NCT03424018
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
AchondroplasiaBMN 111
brief summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
started
Dec 12, 2017
primary completion
Jun 1, 2031
completion
Jun 1, 2031
last updated
Mar 13, 2026
official title
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol